Login to Your Account

Spinifex's Neuropathic Pain Drug Proves Mettle in Phase II

By Nuala Moran
Staff Writer

Tuesday, August 28, 2012

LONDON – Spinifex Pharmaceuticals announced positive Phase II results of EMA401 in controlling neuropathic pain following herpes zoster (shingles) infection, and the company is now weighing the commercialization strategy for the product.

The study delivers the first clinical proof of efficacy in a new approach to treating neuropathic pain by blocking angiotensin II Type 2 (AT2), a receptor found on neuronal cells that perpetuates the hypersensitive response that is the hallmark of that form of chronic pain.

Tom McCarthy, CEO, said while there are existing treatments for neur

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription